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Abdominal pain is an important symptom in most patients with pancreatic ductal adenocarcinoma
(PDAC). Adequate control of pain is often unsatisfactory due to limited treatment options and signiﬁcant
variation in local practice, emphasizing the need for a multidisciplinary approach. This review contends
that improvement in the management of PDAC pain will result from a synthesis of best practice and
evidence around the world in a multidisciplinary way. To improve clinical utility and evaluation, the
evidence was rated according to the GRADE guidelines by a group of international experts. An algorithm
is presented, which brings together all currently available treatment options. Pain is best treated early on
with analgesics with most patients requiring opioids, but neurolytic procedures are often required later
in the disease course. Celiac plexus neurolysis offers medium term relief in a substantial number of
patients, but other procedures such as splanchnicectomy are also available. Palliative chemotherapy also
provides pain relief as a collateral beneﬁt. It is stressed that the assessment of pain must take into ac-
count the broader context of other physical and psychological symptoms. Adjunctive treatments for pain,
depression and anxiety as well as radiotherapy, endoscopic therapy and neuromodulation may be
required in selected patients. There are few comparative studies to help deﬁne which combination and
order of these treatment options should be applied. New pain therapies are emerging and could for
example target neural transmitters. However, until better methods are available, management of pain
should be individualized in a multidisciplinary setting to ensure optimal care.
© 2018 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ases & Mech-Sense, Depart-
Institute, Aalborg University
B.V. This is an open access article uIntroduction and methods
Pancreatic ductal adenocarcinoma (PDAC) presents in different
ways and often at an advanced stage. Abdominal pain is an
important presenting symptom in about 60% of patients [1] andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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course of the disease. It is a common disabling symptom with
several causes, and often difﬁcult to treat, requiring multidisci-
plinary management for effective control. Pain is also a major
predictor of outcome and survival. A striking ubiquitous patho-
logical feature of PDAC is perineural invasion, which might explain
its propensity to cause pain.
Recently published guidelines reveal a lack of standardized
assessment and management of pain associated with PDAC. Most
recommendations for its management are offered within selected
specialties, reﬂecting signiﬁcant variation in practice and thus
emphasizing the need for a multidisciplinary approach. The varia-
tion in recommendations may simply reﬂect customary practice,
but also the paucity of evidence on which to base the
recommendations.
This review contends that improvement in the management of
PDAC pain will result from a synthesis of best practices and evi-
dences from around the world, to integrate the many treatment
options, including pharmaceuticals, endoscopic and endosono-
graphic interventions, surgery, neurolysis, neuromodulation,
radiotherapy, psychotherapy, nursing and supportive care.
Accordingly, the authors were selected to include a wide range of
specialists with clinical and research experience in cancer pain
management within relevant specialties. The authors were
assigned to make recommendations on PDAC pain related issues
and giving best available evidence. To improve clinical utility, most
recommendations were framed for routine clinical practice. To
score the strength of the evidence a modiﬁed GRADE method was
used (http://www.uptodate.com/home/grading-tutorial). Finally,
the level of agreement for the stated recommendation was deter-
mined by the authors independently voting on-line. Further details
relating to methodology and a fuller discussion are available
(supplementary material on-line).
Pathogenesis of pain in PDAC
The pathogenesis of pain in PDAC is multifactorial and encom-
passes neuropathic, visceral and somatic mechanisms. Quality
assessment: moderate; Recommendation: moderate; Agreement:
strong
The majority of patients with PDAC experience a chronic pain
syndrome that is multifactorial in origin [2]. It entails neuropathic
mechanisms due to neural inﬁltration by cancer cells. However, the
pathogenesis of pain in PDAC is additionally complex in most cases
with evidence of cross talks between pancreatic nerves, vascular
system, pancreatic stellate cells and cancer cells. This is reﬂected in
management that should target several mechanisms. In addition,
pain can be due to invasion of other visceral and somatic structures.
For details and references, see supplementary material.
Pain assessment in PDAC
Pain should be assessed in the context of many other physical and
psychological symptoms, with an emphasis on severity, quality,
distress and functional consequences. Although there has been focus
on pain intensity, pain interference with quality of life should also be
addressed. Quality assessment: moderate; Recommendation: strong;
Agreement: strong
Pain should be assessed in the context of other multiple physical
and psychological symptoms, with an emphasis on severity, quality,
distress and functional consequences from a patient's perspective
[3]. As pain in PDAC shares mechanisms with those in chronic
pancreatitis, assessment tools used in this disease may be adopted
to patients with pancreas cancer [4]. Numerical scales, such as the
visual analogue scale, are commonly applied to assess the intensityof pain, but should be combined with a standardized registration of
the temporal pain pattern [5]. Patients with PDAC have a very high
prevalence of depressed mood, which is higher than other cancers
with similar prognoses [6] and in many cases disturbed sleep and
fatigue should also be recorded [7]. Pain assessment should also be
supplemented with measurement of quality of life (QoL) using in-
struments such as the Short-FormHealth Survey 36 (SF-36) and the
European Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 [8,9].
Secondary reasons for pain
Pain due to complications associated with treatment and side ef-
fects of medication is frequent and should always be considered as
additional reason for pain, especially because treatment is often
effective. Quality assessment: low; Recommendation: moderate;
Agreement: strong
Adverse effects and complications due to surgery, endoscopic,
pharmacological and oncological treatments are important cau-
ses of morbidity in many patients and should be considered as
additional sources of pain (Table 1). As management is often
effective, these causes of pain should not be overlooked. Pain can
be due to chemotherapy and irradiation, and related to neurop-
athy and enteritis [10]. Anastomotic and peptic ulcers are com-
mon and there should be a low threshold for endoscopic
diagnosis. Although strong opioids are often used to relieve pain,
they have the potential to produce substantial side effects,
including constipation, abdominal pain and opioid induced
hyperalgesia that can mimic pain due to PDAC (see section on
analgesics). Complications of surgical and endoscopic treatments
can also be the cause of pain. These include anastomotic leaks,
intra-abdominal collections, acute pancreatitis, perforation and
adhesions [11]. Obstruction of the bile duct is almost universal in
PDAC of the head of pancreas, while obstruction of the duo-
denum occurs in up to a quarter of these patients. In patients
with unresectable, metastatic and recurrent PDAC, biliary and
gastric outlet obstructions are best managed with self-expanding
metal stents without the need for surgical bypass, because they
have been demonstrated to be safe and effective [12]. Abdominal
discomfort can be due to maldigestion following pancreatic
resection from a possible combination of exocrine pancreatic
insufﬁciency, bile acid malabsorption and bacterial overgrowth
[4,12]. Advanced PDAC may cause pain due to direct invasion into
adjacent organs but also from metastases, most commonly to
bone, liver and lung [13].
Pain management algorithm
Pain management in PDAC should be individualized, multidisci-
plinary and follow an algorithm. Quality assessment: moderate;
Recommendation: strong; Agreement: strong
Pain management in PDAC should be individualized, but it
will also depend on local expertise and skills. In many clinical
settings, the treatment of pain follows traditional approaches and
several treatment modalities are often overlooked. There is an
overall consensus by pain specialists that optimal management
of cancer pain should be multidisciplinary [13]. This is illustrated
in Fig. 1, where most treatment options are included. The
different treatments are often started in parallel, although the
sequence of treatments will often depend on stage of PDAC and
availability of treatment modalities and expertise. Hence, the
algorithm in Fig. 1 shall not be regarded as deﬁnitive but as
guidance. With a multidisciplinary approach, it is imperative that
patients have rapid access to a lead health care professional to
coordinate disciplines and taking overall responsibility. Ideally,
Table 1
Secondary reasons for pain in patients with PDAC.
Suggested investigation Treatment
Anastomotic and peptic ulcers Gastroscopy Proton pump inhibitors
H. Pylori eradication
Side-effects to opioids Clinical judgement Tapering of medication
Co-administration of laxatives in patients on opioid therapy
Side effects to chemotherapy and irradiation Clinical evaluation Local treatment and drugs against neuropathy
Somatic pain with irradiation to the abdomen Objective assessment of the back etc. Targeted against the somatic pain
Surgical end endoscopic complications: Anastomosis
leaks or strictures, intraabdominal adhesions, pancreatitis
Imaging Conservative treatment, endotherapy or surgery
Duodenal and biliary obstruction Magnetic resonance imaging Stent placement
Exocrine pancreatic insufﬁciency Pancreatic function testing Enzyme replacement therapy
Bacterial overgrowth Breath testing Antibiotics
Bile acid malabsorption Se-HCAT scan Cholestyramine
Delayed gastric emptying Gastroscopy, scintigraphy Pro-kinetics
Metastasis and tumor growth to neighbour organs Imaging Dependent on localization
Se-HCAT: selenium homocholic acid taurine.
Fig. 1. Simpliﬁed algorithm showing the treatment possibilities for optimal management of pain in patients with pancreatic ductal adenocarcinoma. In most cases, the algorithm
cannot be strictly followed and combination therapies are necessary. The recommendation is to consider whether pain intensity and effect on quality of life is sufﬁciently severe to
justify treatment, given the potential side effects. In case there is indication for pain management the following is suggested: 1) First it shall be considered whether there can be
secondary reasons for pain as this often needs speciﬁc treatments. 2) The next step is to evaluate whether local factors such as strictures on the main pancreatic duct need
endoscopical or surgical treatment. 3) Primary pain due to tumor inﬁltration of the nerves and local pressure is treated with a) chemotherapy according to performance status and
pancreatic enzymes as well as b) analgesics, see speciﬁc section for detail. In case this is insufﬁcient or there are too many side effects, c) neurolysis is considered. The neurolytic
treatment depends on local expertise, and timing is important, see speciﬁc section. In many patients d) adjuvant therapy with antidepressants and anxiolytics that also have
analgesic properties are used, and complimentary therapy such as with acupuncture may be used. In some cases, especially when other procedures have failed, treatment with e)
radiotherapy or HIFU can also be used. Finally, 4) supportive care and 5) psychosocial interventions are mandatory in the multidisciplinary approach to pain management. * In
terminal disease spinal application of opioids, anesthetics and adjuvant analgesics may be used for palliation. GI: gastrointestinal, PCM: paracetamol, NSAID: non-steroidal anti-
inﬂammatory drugs, SNRI: serotoninenorepinephrine reuptake inhibitors, TCA: tricyclic antidepressants, BZD: benzodiazepines, TENS: transcutaneous electrical nerve stimulation,
HIFU: high intensity focused ultrasound.
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457448this would be an expert pancreatologist/surgeon/oncologist who
should work with a pain or palliative care specialist. Because the
progress of PDAC and pain is unpredictable, it is important that
patients are well monitored and treatment adjusted.Non-invasive management of PDAC
Pancreatic enzyme replacement therapy
Pancreatic enzyme replacement therapy may diminish pancreas
secretion and normalize gut function, and as such alleviate abdominal
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457 449pain. Quality assessment: moderate; Recommendation: weak; Agree-
ment: weak
Pancreatic enzyme replacement therapy is used for the man-
agement of exocrine pancreatic insufﬁciency in patients with PDAC.
but it may also exert an analgesic effect. The proposed pain reliving
mechanism of action is the ability of pancreatic enzymes to degrade
cholecystokinin (CCK) releasing factor in the duodenum, whereby
CCK-levels are suppressed [14]. In addition to the effects mediated
through CCK pathways, normalization of digestion following
enzyme replacement therapy may also improve abdominal symp-
toms. However, their effect on pain in PDAC is not proven.
Chemotherapy
Chemotherapy can reduce pain likely by decreasing tumor load.
Quality assessment: moderate; Recommendation: strong; Agreement:
conditional
Chemotherapy in unresectable patients may decrease pain by
reducing tumor growth, local neural invasion and inﬂammation. In
a meta-analysis in patients with metastatic PDAC, pain relief
following chemotherapy was consistently seen for most included
studies evaluating pain [15]. Previous studies have shown that
gemcitabine compared with 5FU resulted in increased survival and
reduced pain [16]. Gemcitabine-based combinations showed no
consistent beneﬁt for pain compared with single-agent gemcita-
bine [17]. The newer regimens FOLFIRINOX (oxaliplatin, irinotecan,Table 2
Recommended oral analgesics for treatment of PDAC.
Drug class Examples* C
Non-opioid analgesics paracetamol 1 g x 4 U
n
Weak opioids tramadol CR 50e200mg x 2 C
p
Strong opioids oxycodone PR starting at 15mg x 2 A
es
in
d
Anticonvulsants pregabalin titrated from 75mg to 300mg x 2 daily T
d
TCA amitriptyline 10e50mg at nighttime Si
T
SSRI citalopram titrated up to 40mg at nighttime T
o
SNRI duloxetine titrated up to 120mg at nighttime T
w
Anxiolytics diazepam 5mg x 3 H
Anti-psychotics levomepromazane titrated up to 100mg daily M
a-adrenergic agents clonidine titrated to 50 mg x 2 daily M
si
NMDA inhibitors ketamine titrated up to 50mg x 3 daily A
o
A
Cannabinoids nabilone dose 1e2mg, up to 6mg daily M
Sm
p
Steroids dexamethasone 8mg daily T
Anti-cholinergic drugs hyoscine titrated to 20mg x 4 C
GABA-agonists baclofen titrated from 5 to 25mg x 3 M
Setrons ondansetrone 8mg x 2 N
Somatostatin analogues octreotide depot 20mg every 4th week M
O
NSAID: non-steroidal anti-inﬂammatory drugs.
TCA: tricyclic antidepressants.
SSRI: selective serotonin reuptake inhibitors.
SNRI: serotonin-noradrenalin reuptake inhibitors.
BZD: benzodiazepines.
GABA: gamma-aminobutyric acid.
* Examples are the authors own suggestions and reﬂect their normal practice. This var
drugs etc., and can only be regarded a suggestion for clinical management. For details seﬂuorouracil and leucovorin) and gemcitabine/nab-paclitaxel have
shown improved survival compared to gemcitabine, and are at
present considered standard treatment for patients with good
performance status [17,18], although time until deterioration of
pain is longer for FOLFIRINOX than with gemticabin [15].
Analgesics
Currently the guidelines for analgesic therapy in PDAC follows the
principles of the “analgesic ladder” provided by the World Health
Organization. However, experimental treatment and other analgesics
may be beneﬁcial in the individual patient. In end stage disease, more
aggressive treatment modalities are often needed. Quality assessment:
moderate; Recommendation: strong; Agreement: strong
The “analgesic ladder” is a stepwise escalation of drugs with
increasing analgesic potency until pain relief is obtained [19] (Fig. 1,
for details see supplementary material). Analgesics should prefer-
ably be administered by the oral route (Table 2) at regular intervals.
Breakthrough pain is treated with e.g., fast-acting on-demand
opioids such as fentanyl. To facilitate the clinical use, the authors'
personal recommendations are also shown (Table 2). The most
important drug classes are brieﬂy described below:
Non-opioid analgesics are used as the ﬁrst step in pain man-
agement. Paracetamol may be sufﬁcient for patients in whom the
pain intensity is mild to moderate. Non-steroidal anti-inﬂamma-
tory drugs (NSAIDs) are normally avoided, but may be used with aomments
sed for milder pain. Due to gastrointestinal and cardiac side effects NSAIDS should
ormally be avoided. Metamizole may also be considered.
odeine and tramadol potentiate the effect of non-opioid analgesics. Both are
rodrugs, metabolized to active opioids and may result in the same side effects.
ddiction is not of major concern in PDAC associated with short life-expectancy, but
calation of dose can be problematic and some patients may develop opioid-
duced hyperalgesia. Due to potential organ failure during progression of disease
rugs without active metabolites are preferred.
he therapeutic gain is often limited due to the side effects (mainly drowsiness and
izziness), but often these vanish during treatment
de effects limit their use. The effects appear after several weeks of treatment. If one
CA does not work, another may be effective.
his class is not an effective analgesic, but may be preferred by some patients in case
f comorbid anxiety and depression
he effects of SNRI's are less well documented in cancer pain. They may be used
hen neuropathic pain is suspected, and for comorbid anxiety or depression
ave limited, if any, analgesic effect, but may dampen anxiety
ay potentiate the analgesic effect in selected patients as an augmentation strategy
ay potentiate analgesia when used as add on to the existing treatment, however
de effects limit its use. Most evidence support parenteral and intrathecal use
s the strongest NMDA inhibitor ketamine may be effective, but side effects are
ften severe (treated with concomitant administration of benzodiazepines).
bsorption following oral use is variable but can be used and is suggested here
ostly used as adjunctive pain medication and useful for nausea, appetite and sleep.
all pain reduction and central nervous system side effects limit use in some
atients, considered as third line agent
he anti-inﬂammatory effects may be beneﬁcial in selected cases
an be adjuvant therapy for bowel obstruction
ay be effective in neuropathic pain but is seldom used
ormally used against nausea but may have an analgesic effect
ay be effective in bowel obstruction and potentially also has an analgesic effect.
ral use not possible, but injections with depot formulations may be used
ies between countries and regions and is dependent on traditions, availability of the
e text.
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457450proton pump inhibitor in case of patient preference. Metamizole is
safer for the upper intestinal tract and kidneys than NSAIDs and is
an alternative [20]. For more severe pain, combination therapies
(also with opioids) may be necessary early in the disease. As shown
in Fig. 1, adjuvant analgesics may be added. These are a heteroge-
neous group of drugs, which include antidepressants, anticonvul-
sants, and anxiolytics. In clinical practice, anti-neuropathic
medications, such as gabapentin and amitriptyline, are often used
Most of the analgesics shown in Table 2 have not been systemati-
cally evaluated for pain associated with PDAC. However, pain
mechanisms and symptoms are likely to be similar across different
diseases [21]. In general, combination therapies are often more
effective andmay decrease the risk of side effects if lower doses can
be used for individual drugs [22]. The choice of drugs is also
determined by an assessment of patient co-morbidity, adverse ef-
fects and any desired side effects (such as sleep and anxiolytic
action).
Anxiety and depression can be masked and screening with reli-
able and valid questionnaires can detect signiﬁcant underlying
emotional distress [23]. Such patients may beneﬁt from drugs with
combined analgesic and anti-depressive effects such as
serotoninenorepinephrine reuptake inhibitors (SNRIs) that have
less side effects than traditional tricyclic anti-depressives. Antide-
pressant drugs can also have neuromodulatory analgesic properties
[24]. Psychotherapy should also be considered.
Opioid analgesics are the mainstay in the management of severe
cancer pain. These are highly effective and their appropriate use by
competent clinicians is important. Unfortunately, the drugs are
often difﬁcult to use and treatment may be complicated by severe
adverse effects. The prescriber should therefore follow guideline
recommendations [25e28]. Even with dose escalation, addiction is
seldom a problem in patients with PDAC. Opioids should not be
used alone, but added to a multidisciplinary strategy that includes
all necessary adjuvant analgesics, psychological and social support.
There is enormous variation in opioid availability around theworld,
and insufﬁcient availability can lead to under-treatment [29,30]. In
patients with progressive diseases like PDAC severe renal and he-
patic insufﬁciency may develop over time and some opioids like
codeine, tramadol and morphine require extra caution [25]. All
patients must be fully informed of the proposed therapeutic
strategy and potential side effects. In some cases, the abdominal
pain increases despite an increase in opioid dose, and opioid
induced bowel dysfunction (ileus and constipation) or opioid
induced hyperalgesia (narcotic bowel syndrome) should be sus-
pected [31,32]. Laxatives should be considered for all patients on
opioid analgesia for PDAC pain because of the high risk of con-
stipation. Other strategies include the use of opioid antagonists
with restricted effect on the gut or in the periphery, or in case of
hyperalgesia, opioid rotation or even lowering or tapering off opi-
oids. Patients on opioid therapy must be kept under close clinical
surveillance, and it should be noted that there is considerable in-
dividual variation in both efﬁcacy and side-effects. Not all patients
beneﬁt from opioids and often additional treatments are required.
A trial of an alternative opioidmay also be indicated. Opioid rotation
may be difﬁcult and patients with pain may need higher doses than
patients who are switched because of intolerable side effects
[13,29]. Transdermal administration (patch formulation) may be
useful in patients having trouble with oral intake. Breakthrough
pain can be treated with rapid-onset transmucosal or intranasal
fentanyl formulations. Methadone may be advantageous in many
patients and can be used in small doses as add-on to existing opioid
treatment. Of note, methadone should only by prescribed by phy-
sicians who are familiar with the complex pharmacology and
adverse effect proﬁle of this opioid.
In case of poor pain control, continuous pharmacotherapy bymeans of epidural or intrathecal catheters might be considered.
When pain is caused by liver or bone metastases, patients may
beneﬁt from radiotherapy [12].
Supplementary treatments such as cannabinoids, ketamine,
clonidine, benzodiazepines, anti-psychotics and steroids may be
considered in difﬁcult cases [13]. For management of pain in PDAC,
cannabinoid derivatives are mostly prescribed in the palliative
phase. Nausea, low appetite and poor sleep are additional targets.
Although small series report modest pain relief with dronabinol in
gastro-intestinal cancers, sound clinical evidence is lacking
[33e35]. Evidence is scarce for ketamine in cancer pain. The drug
may reduce opioid-induced tolerance and hyperalgesia which is
beneﬁcial for many patients. The mode of administration is still not
standardized with some support for intravenous or subcutaneous
use [36] or intranasal administration [27].
Near the end-of life, pain management for advanced and ter-
minal PDAC can become very challenging and an interdisciplinary
approach, including palliative care specialists is needed. It is
important wherever possible to consider the preferences of the
patient. Depending on the national legal and ethical framework, a
range of supportive care measures can be offered, including
intensive home support, home carewith parenteral opioids, patient
controlled analgesia and palliative sedation. Finally, in some
countries, patients with terminal cancer have the legal right to
request euthanasia or assisted suicide [37].
Invasive management of PDAC
Neurolytic treatment
Neurolysis in PDAC can reduce pain intensity and opioid use, but as
the duration of effect is highly variable it is normally reserved for
palliating patients with advanced stages of disease and short life ex-
pectancy. Celiac plexus neurolysis is most used and bilateral injection
or direct injection in the ganglia is recommended. The endoscopic
approach may decrease the risk of complications. Other procedures
such splanchnicectomy are less well documented and seldom used,
although it may relieve pain for a longer time period. Quality assess-
ment: moderate; Recommendation: strong; Agreement: strong
Neurolytic procedures of the sympathetic nervous system have
been used for nearly a century to treat pain in patients with PDAC
[38]. The rationale is to reduce pain by destruction of the afferent
pathways from pancreas to the brain, and can be done at different
levels (Fig. 2); for more details please see appendix. One of themost
commonly used procedures is celiac plexus neurolysis (CPN).
Importantly, only the upper abdominal visceral pain sensations are
targeted.
Celiac plexus neurolysis
Technique: The classic technique is the bilateral, percutaneous
posterior approach, guided ﬂuoroscopically or with computed to-
mography. When the needle is in the correct position a neurolytic
agent, typically absolute alcohol, is injected around the nerves [39].
In cases of advanced cancers, the analgesic effect of CPN may be
limited [40], and malignant inﬁltration of the plexus is also a pre-
dictor of poor pain response [41]. While a few studies found no
differences between central versus bilateral injections [42,43], a
randomized study and a meta-analysis have shown superiority of
bilateral injections [44,45].
Efﬁcacy: There is evidence that CPN, regardless of the technique
used, improves analgesia and QoL, and decreases opioid con-
sumption [26,46]. Compared with analgesic drugs, there is minimal
superiority, but CPN is associated with fewer adverse effects
[46,47]. Unfortunately, most studies have focused on pain intensity
rather than more composite endpoints [48], and only a few are
Fig. 2. Different approaches to neurolytic therapy in PDAC. A: Potential levels of neurolysis. 1) Celiac plexus block; 2) Splancnicectomy; 3) Sympathectomy; 4) Rhizotomy. The two
latter are seldom used. B: Schematic illustration of the most used procedures. 1) Percutaneous transcrural celiac plexus neurolysis; 2) Percutaneous retrocrural splancnic nerve
neurolysis (the thoracoscopic splancnicectomy is not shown); 3) Endoscopic ultrasonography-guided celiac plexus neurolysis (bilateral, broad or intraganglionic neurolysis is the
recommended technique).
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457 451considered of high quality [39,46,49]. Importantly, if malignancy
involves areas of somatic innervation such as the peritoneum or
diaphragm, neurolysis will lose its effect.
Timing: Due to the risk of ﬁbrosis and other complications, CPN
is normally not performed before surgery. Some studies proposed
early intervention [50e53]. However, these observations remain
unproven since CPN was often performed in patients receiving
analgesic drugs [54]. The analgesic effect seems to vanish after 8
weeks [49], and in most patients, pain recurs after 3 months [50].
As only about 30% of patients beneﬁt from repeated CPN [55], this is
normally not offered. As the probability of patients remaining
completely pain free after CPN diminishes with increasing survival
time, the optimal therapeutic window may be in later stages of
disease so the effect is maximal when pain intensity is highest
[53,54]. The arguments against late intervention is that tumor
growthmay involve other organs, where CPN is less effective. There
is signiﬁcant variation in the analgesia duration, and timing will
differ between patients. Overall there is general agreement that
neurolysis is best reserved for patients with advanced disease, and
indicated when strong analgesics are no longer effective or their
side effects increase QoL [56]. Life expectancy, and extent and rate
of disease progression should be considered in individual patients.
Survival: Weak clinical evidence indicates that opioids (as the
alternative to neurolysis) may play a negative role in cancer
development and progression [57,58]. CPN could at least theoreti-
cally be opioid sparing and prolong survival. Additionally, PDAC has
neurotrophic characteristics and as tumor growth may follow the
nerves, destruction of the pathways could be advantageous [59].
Correspondingly, an early study showed prolongation of survival
after performing CPN [50], but this was not reproduced in later
retrospective studies [60] and there is no robust evidence that CPN
affects progression of disease.
Endoscopic ultrasonography-guided celiac plexus neurolysis
(EUS-CPN): This is becoming increasingly popular as it has fewer
risks. Due to the variation of the anatomy of the celiac trunk, EUS
also has the advantage of allowing direct visualization of the celiac
ganglia [61]. The use of Doppler makes it possible to assess theregional vascular structures and reduce the risk of posterior spread
of the neurolytic agent to the spinal arteries or nerves. Another
advantage is that the procedure can be performed at the same time
as ﬁne needle aspiration for cytology in patients with unresectable
and metastatic PDAC [39,41,62]. Contraindications to EUS-CPN
include uncorrectable coagulopathy, esophageal or cardiac vari-
ces, altered anatomy of the upper digestive tract secondary to
previous surgery, hemodynamic/respiratory instability, large tumor
mass and lymphadenopathy [62].
No large trials have directly compared EUS-CPN with the clas-
sical percutaneous approach, but relief of pain was reported in
54%e88% of cases in several case series together with a decrease in
opioid consumption [41,63e65]. In most case series, the duration of
pain relief in the successful treatment group was reported around a
median of 8e10 weeks and until death in one third of patients
[41,62,66]. Like for the percutaneous approach, bilateral injection of
the celiac plexus seems to provide better pain relief than injecting
at one site [44,65]. Broad neurolysis and direct injection into the
celiac ganglia may also be better than unilateral injections [67,68].
Splanchnic nerve neurolysis
Splanchnicectomy may disrupt more nerve pathways than CPN
(Fig. 2) and is a better alternative when there is a large mass in the
region of the celiac plexus. The procedure is most often performed
thoracoscopically under general anesthesia, but can also be per-
formed ﬂuoroscopically as a day care procedure. Splanchnicectomy
is seldom performed in patients with PDAC despite some evidence
of long lasting pain relief and few complications in observational
series [69e72], possibly because the expertise is not widely avail-
able. Splanchnicectomy with radiofrequency ablation seems less
effective, but reports are limited. A retrospective study showed a
long-lasting effect on pain with no severe complications [73], but
randomized trials are lacking.
Other neurolytic techniques
Combined tumor ablation and celiac plexus neurolysis with EUS
was recently shown to be more effective for pain relief and survival
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future treatment [74]. Other endoscopic techniques include celiac
ganglion irradiation with I-125 impregnated seeds [75,76]. In pilot
studies, this has been shown successful in the short run and a recent
meta-analysis conﬁrmed an effect on pain in 80% of patients [77].
Complications of neurolysis
Although CPN is generally safe, common side effects include
transient orthostatic hypotension, diarrhea and back pain. Neuro-
logical complications related to spasm or thrombosis of the anterior
spinal artery are seldom (<0.15%) seen, but cases of paraplegia have
also been reported [78]. Retroperitoneal hemorrhage and infections
may also develop, and peripancreatic and brain abscesses have
been described [79,80] (see Table 3).
Neuromodulation
Acupuncture is a moderately effective treatment for cancer pain,
including PDAC. The evidence for an analgesic effect from trans-
cutaneous electrical nerve stimulation is weak. The procedures can
be considered as supplementary treatments in selected patients.
Quality assessment: low; Recommendation: weak; Agreement:
conditional
Acupuncture has beenwidely used for cancer pain in China, and
appears to be moderately effective in selected patients [56,81]. An
analgesic effect was found using electro-acupuncture compared
with sham in patients with PDAC, and this effect persisted for up to
two days after cessation of treatment [82]. Acupuncture has few if
any side-effects, but is operator dependent and the effect is nor-
mally short-lasting. Therefore, it can be regarded as a supplemen-
tary treatment to other therapies.
The evidence for an analgesic effect with transcutaneous elec-
trical nerve stimulation (TENS) is weak, but may be helpful in
selected patients [83]. Spinal cord stimulation is rarely used
because it is a more invasive and costly procedure for patients that
have a limited life expectancy. Another approach to neuro-
modulation is vagal stimulation, which might be effective in
selected patients [84].
Radiotherapy and ultrasound
Radiotherapy appears to be effective for PDAC pain, but prospectiveTable 3
Frequently asked question about neurolytic therapy.
Clinical question Recommendation
Is CPN better than standard therapy? RCTs have shown that CPN decrease
difference in effect is marginal
When shall CPN be done? The timing cannot be predicted by an
neurolysis done when pain cannot b
months it shall be postponed to the
Can CPN be repeated? Technically it can, but is only effectiv
Which technique shall be used? The EUS approach is considered safe
with major experience in imaging gu
What does tumor localization mean? Localized disease may respond best.
tail) there is no consensus
Does CPN prolong survival? Although there may be a theoretical
Are other techniques for CPN advantageous? There is no solid evidence that other n
broad neurolysis and combined CPN
Has splanchnicectomy any advantages
compared to CPN?
Potentially splanchnicectomy is bette
pathways than CPN. However, comp
Are there any predictors for effect? Tumor location does not seem to int
procedure. Involvement of structures
sympathetic pathways of visceral pai
Are there any technical considerations? The effect seems to be better when t
distribution, and when the celiac gan
CNP: celiac plexus neurolysis and RCT: randomized controlled trialevidence is required before it can be generally recommended. Quality
assessment: low; Recommendation: weak; Agreement: conditional
The effect of radiotherapy on pain has been studied both in
patients with chronic pancreatitis [85] and PDAC [86,87], but the
evidence comes from observational studies. It may be suitable for
frail patients and requires further evaluation [88]. A pilot study
showed that stereotactic radiotherapy (CyberKnife) could alleviate
pain in patients withmetastatic PDAC andmay be useful in selected
cases [89].
Pilot data from observational series suggest that high intensity
focused ultrasound (HIFU) improves pain and physical function
[90,91], and this was conﬁrmed in a recent meta-analysis [92].
Despite this, the heterogeneity of the data and the lack of ran-
domized controlled trials prevents making a strong
recommendation.Endoscopic treatment
Pancreatic ductal stenting can be considered for a small subgroup
of patients with unresectable PDAC in the head of pancreas, dilation of
the main pancreatic duct and severe “obstructive-type” pancreatic
pain. Quality assessment: low; Recommendation: moderate; Agree-
ment: conditional
Several case series have reported that pancreatic ductal stenting
can help to palliate pain [93]. It appears that this is indicated in a
small subgroup of patients with unresectable PDAC in the head of
pancreas, associated with dilation of the main pancreatic duct
(MPD) and with severe pancreatic obstructive-type of pain (see
supplementary material). Pain relief was reported in about 80% of
these cases [93]. A prospective study reported a decrease in pain
intensity and reduced opioid consumption over 16 weeks in 62% of
patients [94]. In another prospective study, it was found that pain
relief was only found in patients with a dilatedMPD [95]. Pancreatic
ductal stenting could therefore be considered in those patients
with unresectable pancreatic cancer in the head of pancreas, severe
“obstructive-type” pancreatic pain, and MPD dilatation. While this
could be considered at the same time as biliary stenting, there is a
lack of randomized controlled studies comparing it with other pain
treatment and it cannot be recommended as a standard of care [96].pain and opioid consumption in comparison with conventional therapy, but the
y clinical parameters. Most studies recommend that analgesics are used ﬁrst and
e controlled or opioid consumption is accelerated. As efﬁcacy decrease after 2e3
later stages of disease and life expectancy taken into consideration
e in about 30%, partly because tumor growth may extend to other tissue
r although evidence is limited, but when available it is recommended. In centers
ided percutaneous CPN this may be preferred.
Although some studies have shown better effect in certain locations (head, body
gain, clinical studies do not support an effect on disease progression
eurolytic techniques are better, but pilot studies seem to indicate that for example
and tumor ablation gives better response than standard treatment
r when a large mass is present around the celiac plexus and disrupt more nerve
arative studies are lacking.
erfere with pain relief, but involvement of the celiac plexus may complicate the
outside pancreas may also decrease analgesia as neurolysis only blocks the
n
he neurolytic agent has a broad
glia are directly visualized endoscopically and injected
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The role of surgical treatment to palliate pain associated with PDAC
is extremely limited, although surgery may be rarely indicated for pain
due to duodenal or biliary obstruction. Quality assessment: moderate;
Recommendation: strong; Agreement: strong
Historically, surgical treatments were used for the division of
putative pain pathways, including celiac plexi, splanchnic nerves,
sympathetic chain and spinal nerve roots (see Fig. 2). These surgical
neurolytic procedures have fallen into abeyance with the failure of
evidence for a favorable risk:beneﬁt ratio and with the rise of
minimally invasive alternatives [97]. Pain relief is expected when
complete surgical resection of PDAC is possible, as a surgery ﬁrst
approach or after neoadjuvant therapy. However, pain is most
commonly associated with locally advanced PDAC (either primary
or as recurrence), where there is direct tumor extension beyond the
pancreas, along with perineural and lymphovascular invasion.
Because of the morbidity (including pain), risk of mortality and
delayed recovery, palliative pancreatic resections are no longer rec-
ommended [98]. This is reﬂected in the signiﬁcantly reduced need
for surgery as a palliative intervention, and the increasing use of
palliative chemotherapy for stage IV PDAC [99].
Pain can also be due the invasion of adjacent organs by PDAC,
and surgery may play a role in these circumstances. Stenosis of the
distal bile duct can in some cases give rise to biliary type pain with
obstructive jaundice, but endoscopic biliary stenting is now used in
the vast majority of patients [100]. Stenting of the bile duct rarely
gives rise to painful acute cholecystitis [101], and if antibiotics and
endoscopic treatments are not effective, a percutaneous trans-
hepatic cholecystostomy or cholecystectomy may be required.
Stenting can also be associated with ascending cholangitis and pain
and this necessitates stent exchange. Advanced PDAC can also cause
pain associated with gastric outlet obstruction secondary to
duodenal invasion and stenosis. Historically, surgical treatmentwas
used, but endoscopic duodenal stenting is now preferred [100].
Psychosocial interventions
There is moderate evidence in favor of psychosocial interventions
for cancer pain in general, but the evidence is limited for PDAC. Pooled
data suggest moderate efﬁcacy with pain relief. Quality assessment:
moderate; Recommendation: moderate; Agreement: strong
Anxiety and depressive symptoms are common in PDAC, with
rates higher than for other cancers in most studies [102e106]. In
one study, the severity of depression was linked to increased self-
reported pain [105]. Depression has been linked to signiﬁcantly
poorer QoL [107]; sleep disturbance [108], inadequate cancer
treatment and lower survival rates [109]. Because depression,
anxiety, pain, sleep disturbance and negative or pessimistic
thoughts or attitudes are modiﬁable conditions, proper assessment
and management is essential [110].
There has been no randomized control trial of any behavioral
intervention for patients with PDAC, but an open pilot study
showed a beneﬁcial effect of educational sessions by nurses on QoL
[111]. One opinion article recommended a psycho-oncologist for
PDAC patients to distinguish normal emotional reactions to cancer
which usually resolve within weeks, with appropriate social sup-
port from longer lasting psychiatric conditions requiring psycho-
therapy and psychotropic medications [112].
Suggested psychosocial approaches can be drawn from studies
for other types of cancers with a similar psychological symptom
proﬁle. Supportive therapy, cognitive behavioral therapy, coping
skills training, mindfulness meditation, hypnosis, dignity therapy
and acceptance and commitment therapy have the strongest evi-
dence of efﬁcacy [113e120]. Overall, most studies support the ideathat psychosocial interventions offered early in the cancer course
have a more signiﬁcant beneﬁt than those offered at end-stage
disease [121,122].
Supportive and palliative care
The provision of palliative care to patients with newly diagnosed
and incurable PDAC improves quality of life, reduces depression, and
an analgesic effect is expected. Quality assessment: low; Recommen-
dation: moderate; Agreement: strong
The goal of palliative care, in taking a holistic approach to care
and treatment, is to improve the QoL of patients with advanced
cancer by alleviating symptoms and problems caused by illness and
its treatment [123]. The early provision of palliative and oncology
care in patients with newly diagnosed incurable cancers (including
PDAC) improves QOL, reduces depression symptoms, and enhances
the ability to cope with the diagnosis and prognosis [124,125]. As a
result, an analgesic effect is expected. A recent retrospective study
showed that patients with advanced PDAC beneﬁted from a palli-
ative care programs by requiring less chemotherapy and less
admission to intensive care and hospital [126]. Palliative care of
patients with PDAC should include nutritional support and opti-
mized pancreatic enzyme replacement [12].
Systematic early palliative care was shown to be superior to on-
demand palliative care in terms of QoL (and probably pain relief)
[127]. The actual evidence for the efﬁcacy of early palliative care
interventions is still sparse, but it generally accepted that this
should be recommended for all patients with advanced PDAC.
Conclusion
Unfortunately, most patients with pancreatic ductal adenocar-
cinoma have unresectable disease and succumb to local recurrence
and metastatic disease. Therefore, they often need advanced ther-
apy as part of palliative care. The overall management requires the
coordination of multiple disciplines and this is particularly true for
associated pain, which can be disabling and arises due to a number
of different mechanisms. The assessment of pain must take into
account other symptoms and the broader context of other physical
and psychological symptoms. The many treatment options have
been reviewed and an international, multidisciplinary consensus
obtained, including the strength of recommendation and the extent
of agreement. An algorithm is presented which brings together all
treatment options, but there are few comparative studies to help
deﬁne which combination and order of these treatment options
should be applied to the management of individual patients. This
might go some way to explaining the variation of practice and
opinion, amongst international experts. Management of pain
should always be multimodal and individualized, and will depend
on factors such as disease stage, patient preferences and local
expertise. However, it is strongly recommended that all possible
treatment options are considered, preferably in a multidisciplinary
setting, to ensure optimal care.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.pan.2018.04.008.
References
[1] Lakatos G, Balazs A, Kui B, Godi S, Szücs A, Szentesi A, et al. Pancreatic cancer:
multicenter prospective data collection and analysis by the Hungarian
pancreatic study group [cited 2017 Oct 13] J Gastrointest Liver Dis 2016
Jun;25(2):219e25. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/
27308654.
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457454[2] Russell RC. Palliation of pain and jaundice: an overview [cited 2017 Oct 16]
Ann Oncol Off J Eur Soc Med Oncol 1999;10(Suppl 4):165e9. Available from:,
http://www.ncbi.nlm.nih.gov/pubmed/10436814.
[3] Tang C-C, Von Ah D, Fulton JS. The symptom experience of patients with
advanced pancreatic cancer: an integrative review [cited 2017 Oct 16]
Cancer Nurs 2017 Jan 4;1. Available from:, http://insights.ovid.com/crossref?
an¼00002820-900000000-99268.
[4] Drewes AM, Bouwense SAWW, Campbell CM, Ceyhan GO, Delhaye M,
Demir IE, et al. Guidelines for the understanding and management of pain in
chronic pancreatitis [cited 2017 Oct 16] 2017 Sep 1;17(5):720e31. Available
from:, http://linkinghub.elsevier.com/retrieve/pii/S142439031730515X.
[5] Mullady DK, Yadav D, Amann ST, O'Connell MR, Barmada MM, Elta GH, et al.
Type of pain, pain-associated complications, quality of life, disability and
resource utilisation in chronic pancreatitis: a prospective cohort study [cited
2017 Mar 7] Gut 2011 Jan 1;60(1):77e84. Available from:, http://gut.bmj.
com/cgi/doi/10.1136/gut.2010.213835.
[6] Clark KL, Loscalzo M, Trask PC, Zabora J, Philip EJ. Psychological distress in
patients with pancreatic cancerean understudied group [cited 2017 Oct 16]
Psychooncology 2010 Dec;19(12):1313e20. Available from:, http://doi.wiley.
com/10.1002/pon.1697.
[7] Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, et al.
Research design considerations for conﬁrmatory chronic pain clinical trials:
IMMPACT recommendations [cited 2017 Mar 7] Pain 2010 May;149(2):
177e93. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/20207481.
[8] McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health
Survey (SF-36): II. Psychometric and clinical tests of validity in measuring
physical and mental health constructs [cited 2017 Oct 16] Med Care 1993
Mar;31(3):247e63. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/
8450681.
[9] Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, et al.
Development of a disease speciﬁc quality of life (QoL) questionnaire module
to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in
patients with pancreatic cancer. EORTC Study Group on Quality of Life [cited
2017 Oct 16] Eur J Cancer 1999 Jun;35(6):939e41. Available from:, http://
www.ncbi.nlm.nih.gov/pubmed/10533475.
[10] Hidalgo M, Alvarez R, Gallego J, Guillen-Ponce C, Laquente B, Macarulla T,
et al. Consensus guidelines for diagnosis, treatment and follow-up of patients
with pancreatic cancer in Spain [cited 2017 Oct 16] Clin Transl Oncol 2017
Jun 19;19(6):667e81. Available from:, http://www.ncbi.nlm.nih.gov/
pubmed/27995549.
[11] Kapoor VK. Complications of pancreato-duodenectomy [cited 2017 Oct 16]
Rozhl Chir 2016 Feb;95(2):53e9. Available from:, http://www.ncbi.nlm.nih.
gov/pubmed/27008166.
[12] Laquente B, Calsina-Berna A, Carmona-Bayonas A, Jimenez-Fonseca P, Peiro I,
Carrato A. Supportive care in pancreatic ductal adenocarcinoma [cited 2017
Oct 16] Clin Transl Oncol 2017 Nov 13;19(11):1293e302. Available from:,
http://www.ncbi.nlm.nih.gov/pubmed/28612201.
[13] Portenoy RK. Treatment of cancer pain [cited 2017 Oct 16] Lancet 2011 Jun
25;377(9784):2236e47. Available from:, http://www.ncbi.nlm.nih.gov/
pubmed/21704873.
[14] Lieb JG, Forsmark CE. Review article: pain and chronic pancreatitis [cited
2017 Oct 16] Aliment Pharmacol Ther 2009 Apr 1;29(7):706e19. Available
from:, http://doi.wiley.com/10.1111/j.1365-2036.2009.03931.x.
[15] Kristensen A, Vagnildhaug OM, Grønberg BH, Kaasa S, Laird B, Solheim TS.
Does chemotherapy improve health-related quality of life in advanced
pancreatic cancer? A systematic review [cited 2017 Oct 16] Crit Rev Oncol
Hematol 2016 Mar;99:286e98. Available from:, http://linkinghub.elsevier.
com/retrieve/pii/S1040842816300087.
[16] Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR,
et al. Improvements in survival and clinical beneﬁt with gemcitabine as ﬁrst-
line therapy for patients with advanced pancreas cancer: a randomized trial
[cited 2017 Oct 31] J Clin Oncol 1997 Jun;15(6):2403e13. Available from:,
http://ascopubs.org/doi/10.1200/JCO.1997.15.6.2403.
[17] Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer [cited 2017
Oct 31] N Engl J Med 2011 May 12;364(19):1817e25. Available from:, http://
www.ncbi.nlm.nih.gov/pubmed/21561347.
[18] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
[cited 2017 Oct 31] N Engl J Med 2013 Oct 31;369(18):1691e703. Available
from:, http://www.ncbi.nlm.nih.gov/pubmed/24131140.
[19] Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain man-
agement. Stepping up the quality of its evaluation [cited 2017 Mar 8] JAMA
1995 Dec 20;274(23):1870e3. Available from:, http://www.ncbi.nlm.nih.
gov/pubmed/7500538.
[20] Konijnenbelt-Peters J, van der Heijden C, Ekhart C, Bos J, Bruhn J, Kramers C.
Metamizole (dipyrone) as an alternative agent in postoperative analgesia in
patients with contraindications for nonsteroidal anti-inﬂammatory drugs
[cited 2017 Oct 16] Pain Pract 2017 Mar;17(3):402e8. Available from:,
http://doi.wiley.com/10.1111/papr.12467.
[21] Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D.
Neuropathic pain: are there distinct subtypes depending on the aetiology or
anatomical lesion? [cited 2017 Jun 21] Pain 2008 Aug 31;138(2):343e53.
Available from:, http://www.ncbi.nlm.nih.gov/pubmed/18289791.
[22] Holbech JV, Bach FW, Finnerup NB, Brøsen K, Jensen TS, Sindrup SH.Imipramine and pregabalin combination for painful polyneuropathy: a
randomized controlled trial [cited 2017 Oct 16] Pain 2015 May;156(5):
958e66. Available from:, http://content.wkhealth.com/linkback/openurl?
sid¼WKPTLP:landingpage&an¼00006396-201505000-00023.
[23] Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital
Anxiety and Depression Scale. An updated literature review [cited 2017 Oct
16] J Psychosom Res 2002 Feb;52(2):69e77. Available from:, http://www.
ncbi.nlm.nih.gov/pubmed/11832252.
[24] Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and
immunological basis of action of antidepressants in chronic pain-clinical and
experimental studies [cited 2017 Oct 16] Pharmacol Rep 2013;65(6):
1611e21. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/24553009.
[25] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for
chronic PaineUnited States. 2016 Apr 19 [cited 2017 Mar 8] JAMA
2016;315(15):1624e45. Available from:, http://jama.jamanetwork.com/
article.aspx?doi¼10.1001/jama.2016.1464.
[26] Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of
opioid analgesics in the treatment of cancer pain: evidence-based recom-
mendations from the EAPC [cited 2017 Oct 16] Lancet Oncol 2012 Feb;13(2):
e58e68. Available from:, http://linkinghub.elsevier.com/retrieve/pii/
S1470204512700402.
[27] Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical
guidelines for the use of chronic opioid therapy in chronic noncancer pain
[cited 2017 Oct 16] J Pain 2009 Feb;10(2):113e30. e22. Available from:,
http://www.ncbi.nlm.nih.gov/pubmed/19187889.
[28] O'Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, et al.
European Pain Federation position paper on appropriate opioid use in
chronic pain management [cited 2017 Mar 16] Eur J Pain 2017 Jan;21(1):
3e19. Available from:, http://doi.wiley.com/10.1002/ejp.970.
[29] Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L,
et al. Differences between opioids: pharmacological, experimental, clinical
and economical perspectives [cited 2017 Mar 8] Br J Clin Pharmacol 2013
Jan;75(1):60e78. Available from:, http://doi.wiley.com/10.1111/j.1365-
2125.2012.04317.x.
[30] Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country,
global, and regional levels in 2010, its relationship with development level,
and changes compared with 2006 [cited 2017 Oct 16] J Pain Symptom
Manage 2014 Feb;47(2):283e97. Available from:, http://linkinghub.elsevier.
com/retrieve/pii/S0885392413002728.
[31] Drewes AM, Munkholm P, Simren M, Breivik H, Kongsgaard UE,
Hatlebakk JG, et al. Deﬁnition, diagnosis and treatment strategies for opioid-
induced bowel dysfunctiondrecommendations of the Nordic Working
Group [cited 2017 Mar 15] Scand J Pain 2016 Apr;11:111e22. Available
from:, http://linkinghub.elsevier.com/retrieve/pii/S1877886015001469.
[32] Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update
[cited 2017 Mar 8] Am J Gastroenterol Suppl 2014 Sep 10;2(1):22e30.
Available from:, http://www.nature.com/doiﬁnder/10.1038/ajgsup.2014.6.
[33] Goyal H, Singla U, Gupta U, May E. Role of cannabis in digestive disorders
[cited 2017 Oct 16] Eur J Gastroenterol Hepatol 2017 Feb;29(2):135e43.
Available from:, http://www.ncbi.nlm.nih.gov/pubmed/27792038.
[34] Tsang CC, Giudice MG. Nabilone for the management of pain [cited 2017 Oct
16] Pharmacotherapy 2016 Mar;36(3):273e86. Available from:, http://doi.
wiley.com/10.1002/phar.1709.
[35] Davis MP. Cannabinoids for symptom management and cancer therapy: the
evidence [cited 2017 Oct 16] J Natl Compr Cancer Netw 2016 Jul;14(7):
915e22. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/27407130.
[36] Okon T. Ketamine: an introduction for the pain and palliative medicine
physician [cited 2017 Oct 16] Pain Physician 2007 May;10(3):493e500.
Available from:, http://www.ncbi.nlm.nih.gov/pubmed/17525784.
[37] MPR de Castro, Antunes GC, Marcon LMP, Andrade LS, Rückl S, Andrade VLA^,
et al. Eutanasia e suicídio assistido em países ocidentais: revis~ao sistematica
[cited 2017 Oct 16] Rev Bioetica 2016 Aug;24(2):355e67. Available from:,
http://www.scielo.br/scielo.php?script¼sci_arttext&pid¼S1983-
80422016000200355&lng¼pt&tlng¼pt.
[38] Kappis M. Sensibilitat und lokale anasthesie im chirurgischen gebeit der
bauchkokle mit besonderer berucksichtigung der splanchnicusanasthesie.
In: Beitr Klin Chir, vol. 1919; 1919. p. 161e75.
[39] Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus
block for pancreatic cancer pain in adults [cited 2017 Oct 16];(3):CD007519.
In: Arcidiacono PG, editor. Cochrane database syst rev [Internet]; 2011 Mar
16. Available from:, http://doi.wiley.com/10.1002/14651858.CD007519.
pub2.
[40] Rykowski JJ, Hilgier M. Efﬁcacy of neurolytic celiac plexus block in varying
locations of pancreatic cancer: inﬂuence on pain relief [cited 2017 Oct 16]
Anesthesiology 2000 Feb;92(2):347e54. Available from:, http://www.ncbi.
nlm.nih.gov/pubmed/10691219.
[41] Iwata K, Yasuda I, Enya M, Mukai T, Nakashima M, Doi S, et al. Predictive
factors for pain relief after endoscopic ultrasound-guided celiac plexus
neurolysis [cited 2017 Oct 16] 2011 Apr;23(2). Available from:, http://doi.
wiley.com/10.1111/j.1443-1661.2010.01046.x.
[42] LeBlanc JK, Al-Haddad M, McHenry L, Sherman S, Juan M, McGreevy K, et al.
A prospective, randomized study of EUS-guided celiac plexus neurolysis for
pancreatic cancer: one injection or two? [cited 2017 Oct 16] Gastrointest
Endosc 2011 Dec;74(6):1300e7. Available from:, http://www.ncbi.nlm.nih.
gov/pubmed/22000795.
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457 455[43] Tellez-Avila FI, Romano-Munive AF, Herrera-Esquivel J de J, Ramírez-
Luna MA. Central is as effective as bilateral endoscopic ultrasound-guided
celiac plexus neurolysis in patients with unresectable pancreatic cancer
[cited 2017 Oct 16] Endosc Ultrasound 2013 Jul;2(3):153e6. Available from:,
http://www.ncbi.nlm.nih.gov/pubmed/24949384.
[44] Sahai AV, Lemelin V, Lam E, Paquin SC. Central vs. bilateral endoscopic
ultrasound-guided celiac plexus block or neurolysis: a comparative study of
short-term effectiveness [cited 2017 Oct 16] Am J Gastroenterol 2009 Feb
6;104(2):326e9. Available from:, http://www.nature.com/doiﬁnder/10.
1038/ajg.2008.64.
[45] Lu F, Dong J, Tang Y, Huang H, Liu H, Song L, et al. Bilateral vs. unilateral
endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain
management in patients with pancreatic malignancy: a systematic review
and meta-analysis [cited 2017 Oct 16] Support Care Cancer 2018 Feb;26(2):
353e9. https://doi.org/10.1007/s00520-017-3888-0. Available from:, http://
www.ncbi.nlm.nih.gov/pubmed/28956176.
[46] Mercadante S, Klepstad P, Kurita GP, Sjøgren P, Giarratano A. European
Palliative Care Research Collaborative (EPCRC). Sympathetic blocks for
visceral cancer pain management: a systematic review and EAPC recom-
mendations [cited 2017 Oct 23] Crit Rev Oncol Hematol 2015 Dec;96(3):
577e83. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/26297518.
[47] Johnson CD, Berry DP, Harris S, Pickering RM, Davis C, George S, et al. An
open randomized comparison of clinical effectiveness of protocol-driven
opioid analgesia, celiac plexus block or thoracoscopic splanchnicectomy for
pain management in patients with pancreatic and other abdominal malig-
nancies [cited 2017 Oct 23] Pancreatology 2009 Jan;9(6):755e63. Available
from:, http://linkinghub.elsevier.com/retrieve/pii/S1424390309801130.
[48] Dworkin RH. Mechanism-based treatment of pain [cited 2017 Oct 16] Pain
2012 Nov;153(11):2300. Available from:, http://www.ncbi.nlm.nih.gov/
pubmed/23006799.
[49] Nagels W, Pease N, Bekkering G, Cools F, Dobbels P. Celiac plexus neurolysis
for abdominal cancer pain: a systematic review [cited 2017 Oct 16] Pain Med
2013 Aug 1;14(8):1140e63. Available from:, https://academic.oup.com/
painmedicine/article-lookup/doi/10.1111/pme.12176.
[50] Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical
splanchnicectomy in patients with unresectable pancreatic cancer. A pro-
spective randomized trial [cited 2017 Oct 16] Ann Surg 1993 May;217(5):
447e55. 7. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/7683868.
[51] Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S. Prospective ran-
domized double-blind trial of neurolytic coeliac plexus block in patients with
pancreatic cancer [cited 2017 Oct 23] Br J Surg 1998 Feb;85(2):199e201.
Available from:, http://www.blackwell-synergy.com/links/doi/10.1046/j.
1365-2168.1998.00563.x.
[52] Staats PS, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus
block, pain, and mood on longevity in patients with unresectable pancreatic
cancer: a double-blind, randomized, placebo-controlled study [cited 2017
Oct 23] Pain Med 2001 Mar 1;2(1):28e34. Available from:, http://www.ncbi.
nlm.nih.gov/pubmed/15102315.
[53] Ischia S, Ischia A, Polati E, Finco G. Three posterior percutaneous celiac plexus
block techniques. A prospective, randomized study in 61 patients with
pancreatic cancer pain [cited 2017 Oct 23] Anesthesiology 1992 Apr;76(4):
534e40. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/1550278.
[54] Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-
blind, controlled trial of early endoscopic ultrasound-guided celiac plexus
neurolysis to prevent pain progression in patients with newly diagnosed,
painful, inoperable pancreatic cancer [cited 2017 Oct 23] J Clin Oncol 2011
Sep 10;29(26):3541e6. Available from:, http://ascopubs.org/doi/10.1200/
JCO.2010.32.2750.
[55] McGreevy K, Hurley RW, Erdek MA, Aner MM, Li S, Cohen SP. The effec-
tiveness of repeat celiac plexus neurolysis for pancreatic cancer: a pilot study
[cited 2017 Oct 16] Pain Pract 2013 Feb;13(2):89e95. Available from:, http://
www.ncbi.nlm.nih.gov/pubmed/22568823.
[56] Amr YM, Makharita MY. Comparative study between 2 protocols for man-
agement of severe pain in patients with unresectable pancreatic cancer: one-
year follow-up [cited 2017 Oct 19] Clin J Pain 2013 Sep;29(9):807e13.
Available from:, http://content.wkhealth.com/linkback/openurl?
sid¼WKPTLP:landingpage&an¼00002508-201309000-00009.
[57] Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: a
new target for cancer therapy? [cited 2017 Oct 16] Cancer 2015 Aug
15;121(16):2681e8. Available from:, http://doi.wiley.com/10.1002/cncr.
29460.
[58] Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al.
Randomized clinical trial of an implantable drug delivery system compared
with comprehensive medical management for refractory cancer pain: impact
on pain, drug-related toxicity, and survival [cited 2017 Oct 23] J Clin Oncol
2002 Oct 1;20(19):4040e9. Available from:, http://www.ncbi.nlm.nih.gov/
pubmed/12351602.
[59] Akhan O, Ozmen MN, Basgun N, Akinci D, Oguz O, Koroglu M, et al. Long-
term results of celiac Ganglia block: correlation of grade of tumoral invasion
and pain relief [cited 2017 Oct 16] AJR Am J Roentgenol 2004 Apr;182(4):
891e6. Available from:, http://www.ajronline.org/doi/10.2214/ajr.182.4.
1820891.
[60] Oh TK, Lee WJ, Woo SM, Kim NW, Yim J, Kim DH. Impact of celiac plexus
neurolysis on survival in patients with unresectable pancreatic cancer: a
retrospective, propensity score matching analysis [cited 2017 Oct 23] PainPhysician 2017 Mar;20(3):E357e65. Available from:, http://www.ncbi.nlm.
nih.gov/pubmed/28339435.
[61] Yang IY, Oraee S, Viejo C, Stern H. Computed tomography celiac trunk
topography relating to celiac plexus block [cited 2017 Oct 16] Reg Anesth
Pain Med 2011 Jan;36(1):21e5. Available from:, http://www.ncbi.nlm.nih.
gov/pubmed/21455084.
[62] Luz L, Al-Haddad M, DeWitt J. EUS-guided celiac plexus interventions in
pancreatic cancer pain: an update and controversies for the endo-
sonographer [cited 2017 Oct 16] Endosc Ultrasound 2014 Oct;3(4):213.
Available from:, http://www.ncbi.nlm.nih.gov/pubmed/25485268.
[63] Wiechowska-Kozłowska A, Boer K, Wojcicki M, Milkiewicz P. The efﬁcacy
and safety of endoscopic ultrasound-guided celiac plexus neurolysis for
treatment of pain in patients with pancreatic cancer [cited 2017 Oct
16];2012 Gastroenterol Res Pract 2012:503098. Available from:, http://
www.hindawi.com/journals/grp/2012/503098/.
[64] Seicean A, Cainap C, Gulei I, Tantau M, Seicean R. Pain palliation by endo-
scopic ultrasound-guided celiac plexus neurolysis in patients with unre-
sectable pancreatic cancer [cited 2017 Oct 16] J Gastrointest Liver Dis 2013
Mar;22(1):59e64. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/
23539392.
[65] Puli SR, Reddy JBK, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac
plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer
pain: a meta-analysis and systematic review [cited 2017 Oct 16] Dig Dis Sci
2009 Nov 10;54(11):2330e7. Available from:, http://link.springer.com/10.
1007/s10620-008-0651-x.
[66] Si-Jie H, Wei-Jia X, Yang D, Lie Y, Feng Y, Yong-Jian J, et al. How to improve
the efﬁcacy of endoscopic ultrasound-guided celiac plexus neurolysis in pain
management in patients with pancreatic cancer: analysis in a single center
[cited 2017 Oct 16] Surg Laparosc Endosc Percutan Tech 2014 Feb;24(1):
31e5. Available from:, http://content.wkhealth.com/linkback/openurl?
sid¼WKPTLP:landingpage&an¼00129689-201402000-00005.
[67] Ascunce G, Ribeiro A, Reis I, Rocha-Lima C, Sleeman D, Merchan J, et al. EUS
visualization and direct celiac ganglia neurolysis predicts better pain relief in
patients with pancreatic malignancy (with video) [cited 2017 Oct 16] Gas-
trointest Endosc 2011 Feb;73(2):267e74. Available from:, http://linkinghub.
elsevier.com/retrieve/pii/S0016510710022340.
[68] Doi S, Yasuda I, Kawakami H, Hayashi T, Hisai H, Irisawa A, et al. Endoscopic
ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a
randomized multicenter trial [cited 2017 Oct 16] Endoscopy 2013 Apr
24;45(5):362e9. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/
23616126.
[69] Koyyalagunta D, Engle MP, Yu J, Feng L, Novy DM. The effectiveness of
alcohol versus phenol based splanchnic nerve neurolysis for the treatment of
intra-abdominal cancer pain [cited 2017 Oct 16] Pain Physician 2016;19(4):
281e92. Available from:, http://www.ncbi.nlm.nih.gov/pubmed/27228515.
[70] Bhutiani N, Cheadle GA, Bahr MH, Vitale GC. Comparative efﬁcacy of bilateral
thoracoscopic splanchnicectomy for intractable pain secondary to pancreatic
cancer vs chronic pancreatitis [cited 2017 Oct 16] J Am Coll Surg 2017
Apr;224(4):566e71. Available from:, http://linkinghub.elsevier.com/
retrieve/pii/S1072751517301175.
[71] Smigielski J, Piskorz L, Wawrzycki M, Kutwin L, Misiak P, Brocki M. Assess-
ment of quality of life in patients with non-operated pancreatic cancer after
videothoracoscopic splanchnicectomy [cited 2017 Oct 18] Wideochirurgia i
inne Tech maloinwazyjne Videosurgery other miniinvasive Tech 2011
Sep;6(3):132e7. Available from:, http://www.termedia.pl/doi/10.5114/
wiitm.2011.24690.
[72] Buscher HCJL, Schipper EE, Wilder-Smith OHG, Jansen JBMJ, van Goor H.
Limited effect of thoracoscopic splanchnicectomy in the treatment of severe
chronic pancreatitis pain: a prospective long-term analysis of 75 cases [cited
2017 Oct 16] Surgery 2008 Jun;143(6):715e22. Available from:, http://
linkinghub.elsevier.com/retrieve/pii/S0039606008001633.
[73] Papadopoulos D, Kostopanagiotou G, Batistaki C. Bilateral thoracic splanchnic
nerve radiofrequency thermocoagulation for the management of end-stage
pancreatic abdominal cancer pain. Pain Physician [Internet]. [cited 2017
Oct 16];16(2):125e133. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/23511679.
[74] Facciorusso A, Di Maso M, Serviddio G, Larghi A, Costamagna G,
Muscatiello N. Echoendoscopic ethanol ablation of tumor combined with
celiac plexus neurolysis in patients with pancreatic adenocarcinoma [cited
2017 Oct 23] J Gastroenterol Hepatol 2017 Feb;32(2):439e45. Available
from:, http://doi.wiley.com/10.1111/jgh.13478.
[75] Wang K-X, Jin Z-D, Du Y-Q, Zhan X-B, Zou D-W, Liu Y, et al. EUS-guided celiac
ganglion irradiation with iodine-125 seeds for pain control in pancreatic
carcinoma: a prospective pilot study [cited 2017 Oct 16] Gastrointest Endosc
2012 Nov;76(5):945e52. Available from:, http://linkinghub.elsevier.com/
retrieve/pii/S0016510712023334.
[76] Lu Z, Dong T-H, Si P-R, Shen W, Bi Y-L, Min M, et al. Continuous low-dose-
rate irradiation of Iodine-125 seeds inhibiting perineural invasion in
pancreatic cancer [cited 2017 Oct 16] Chin Med J (Engl) 2016;129(20):
2460e8. Available from:, http://www.cmj.org/text.asp?2016/129/20/2460/
191777.
[77] Han Q, Deng M, Lv Y, Dai G. Survival of patients with advanced pancreatic
cancer after iodine125 seeds implantation brachytherapy [cited 2017 Oct 18]
Medicine (Baltimore) 2017 Feb;96(5):e5719. Available from:, http://www.
ncbi.nlm.nih.gov/pubmed/28151849.
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457456[78] K€oker IH, Aralas¸mak A, Ünver N, Asil T, S¸entürk H. Spinal cord ischemia after
endoscopic ultrasound guided celiac plexus neurolysis: case report and re-
view of the literature [cited 2017 Oct 16] Scand J Gastroenterol 2017 Oct
3;52(10):1158e61. Available from:, https://www.tandfonline.com/doi/full/
10.1080/00365521.2017.1335771.
[79] Gress F, Schmitt C, Sherman S, Ciaccia D, Ikenberry S, Lehman G. Endoscopic
ultrasound-guided celiac plexus block for managing abdominal pain asso-
ciated with chronic pancreatitis: a prospective single center experience
[cited 2017 Oct 16] Am J Gastroenterol 2001 Feb;96(2):409e16. Available
from:, http://www.nature.com/doiﬁnder/10.1111/j.1572-0241.2001.03551.
x.
[80] Lalueza A, Lopez-Medrano F, del Palacio A, Alhambra A, Alvarez E, Ramos A,
et al. Cladosporium macrocarpum brain abscess after endoscopic ultrasound-
guided celiac plexus block [cited 2017 Oct 16] Endoscopy 2011 Oct
26;43(Suppl 2). UCTN(S 02):E9-10. Available from:, http://www.thieme-
connect.de/DOI/DOI?10.1055/s-0030-1255804.
[81] Wu X, Chung VCH, Hui EP, Ziea ETC, Ng BFL, Ho RST, et al. Effectiveness of
acupuncture and related therapies for palliative care of cancer: overview of
systematic reviews [cited 2017 Oct 16] Sci Rep 2015 Nov 26;5(1):16776.
Available from:, http://www.nature.com/articles/srep16776.
[82] Chen H, Liu T-Y, Kuai L, Zhu J, Wu C-J, Liu L-M. Electroacupuncture treatment
for pancreatic cancer pain: a randomized controlled trial [cited 2017 Oct 16]
Pancreatology 2013 Nov;13(6):594e7. Available from:, http://www.ncbi.
nlm.nih.gov/pubmed/24280575.
[83] Bao Y, Kong X, Yang L, Liu R, Shi Z, Li W, et al. Complementary and alternative
medicine for cancer pain: an overview of systematic reviews [cited 2017 Oct
16];2014 Evid Based Complement Alternat Med 2014:170396. Available
from:, https://www.hindawi.com/journals/ecam/2014/170396/.
[84] Chwistek M. Recent advances in understanding and managing cancer pain
[cited 2017 Oct 16] F1000Research 2017 Jun 20;6:945. Available from:,
https://f1000research.com/articles/6-945/v1.
[85] Guarner L, Navalpotro B, Molero X, Giralt J, Malagelada J-R. Management of
painful chronic pancreatitis with single-dose radiotherapy [cited 2017 Oct
16] Am J Gastroenterol 2009 Feb 27;104(2):349e55. Available from:, http://
www.nature.com/doiﬁnder/10.1038/ajg.2008.128.
[86] Morganti AG, Trodella L, Valentini V, Barbi S, Macchia G, Mantini G, et al. Pain
relief with short-term irradiation in locally advanced carcinoma of the
pancreas [cited 2017 Oct 16] J Palliat Care 2003;19(4):258e62. Available
from:, http://www.ncbi.nlm.nih.gov/pubmed/14959596.
[87] Wolny-Rokicka E, Sutkowski K, Grza˛dziel A, Dorsz _Z, Tukiendorf A, Lipinski J,
et al. Tolerance and efﬁcacy of palliative radiotherapy for advanced
pancreatic cancer: a retrospective analysis of single-institutional experiences
[cited 2017 Oct 16] Mol Clin Oncol 2016 Jun;4(6):1088e92. Available from:,
https://www.spandidos-publications.com/.
[88] Wang Z, Ren Z-G, Ma N-Y, Zhao J-D, Zhang Z, Ma X-J, et al. Intensity
modulated radiotherapy for locally advanced and metastatic pancreatic
cancer: a mono-institutional retrospective analysis [cited 2017 Oct 16]
Radiat Oncol 2015 Jan 10;10(1):14. Available from:, http://www.ro-journal.
com/content/10/1/14.
[89] Su T-S, Liang P, Lu H-Z, Liang J-N, Liu J-M, Zhou Y, et al. Stereotactic body
radiotherapy using CyberKnife for locally advanced unresectable and met-
astatic pancreatic cancer [cited 2017 Oct 16] World J Gastroenterol 2015 Jul
14;21(26):8156e62. Available from:, http://www.wjgnet.com/1007-9327/
full/v21/i26/8156.htm.
[90] Diana M, Schiraldi L, Liu Y-Y, Memeo R, Mutter D, Pessaux P, et al. High
intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and
the digestive system-current state of the art and future perspectives [cited
2017 Oct 16] Hepatobiliary Surg Nutr 2016 Aug;5(4):329e44. Available
from:, http://hbsn.amegroups.com/article/view/8430/11356.
[91] Shi Y, Ying X, Hu X, Shen H. Pain management of pancreatic cancer patients
with high-intensity focused ultrasound therapy [cited 2017 Sep 18] Pak J
Pharm Sci 2017 Jan;30(1 Suppl):303e7. Available from:, http://www.ncbi.
nlm.nih.gov/pubmed/28625958.
[92] Dababou S, Marrocchio C, Rosenberg J, Bitton R, Pauly KB, Napoli A, et al.
A meta-analysis of palliative treatment of pancreatic cancer with high in-
tensity focused ultrasound [cited 2017 Oct 16] J Ther ultrasound 2017 Dec
1;5(1):9. Available from:, http://jtultrasound.biomedcentral.com/articles/10.
1186/s40349-017-0080-4.
[93] Costamagna G, Mutignani M. Pancreatic stenting for malignant ductal
obstruction [cited 2017 Oct 16] Dig Liver Dis 2004 Sep;36(9):635e8. Avail-
able from:, http://www.ncbi.nlm.nih.gov/pubmed/15460850.
[94] Wehrmann T, Riphaus A, Frenz MB, Martchenko K, Stergiou N. Endoscopic
pancreatic duct stenting for relief of pancreatic cancer pain [cited 2017 Oct
16] Eur J Gastroenterol Hepatol 2005 Dec;17(12):1395e400. Available from:,
http://www.ncbi.nlm.nih.gov/pubmed/16292095.
[95] Gao F, Ma S, Zhang N, Zhang Y, Ai M, Wang B. Clinical efﬁcacy of endoscopic
pancreatic drainage for pain relief with malignant pancreatic duct obstruc-
tion [cited 2017 Oct 16] Asian Pac J Cancer Prev 2014;15(16):6823e7.
Available from:, http://www.ncbi.nlm.nih.gov/pubmed/25169532.
[96] Koulouris AI, Banim P, Hart AR. Pain in patients with pancreatic cancer:
prevalence, mechanisms, management and future developments [cited 2017
Oct 16] Dig Dis Sci 2017 Apr 22;62(4):861e70. Available from:, http://link.
springer.com/10.1007/s10620-017-4488-z.
[97] Dobosz Ł, Kaczor M, Stefaniak TJ. Pain in pancreatic cancer: review of
medical and surgical remedies [cited 2017 Oct 16] ANZ J Surg 2016Oct;86(10):756e61. Available from:, http://doi.wiley.com/10.1111/ans.
13609.
[98] Poruk KE, Wolfgang CL. Palliative management of unresectable pancreas
cancer [cited 2017 Oct 16] Surg Oncol Clin N Am 2016 Apr;25(2):327e37.
Available from:, http://linkinghub.elsevier.com/retrieve/pii/
S1055320715001222.
[99] Kulaylat AS, Mirkin KA, Hollenbeak CS, Wong J. Utilization and trends in
palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S.
population-based study [cited 2017 Oct 16] J Gastrointest Oncol 2017
Aug;8(4):710e20. Available from:, http://jgo.amegroups.com/article/view/
14397/12055.
[100] Gohil VB, Klapman JB. Endoscopic palliation of pancreatic cancer [cited 2017
Oct 16] Curr Treat Options Gastroenterol 2017 Aug 9;15(3):333e48. Avail-
able from:, http://link.springer.com/10.1007/s11938-017-0145-z.
[101] Jang S, Stevens T, Parsi M, Lopez R, Zuccaro G, Dumot J, et al. Association of
covered metallic stents with cholecystitis and stent migration in malignant
biliary stricture [cited 2017 Oct 16] Gastrointest Endosc 2018 Apr;87(4):
1061e70. https://doi.org/10.1016/j.gie.2017.08.024. Available from:, http://
linkinghub.elsevier.com/retrieve/pii/S0016510717322332.
[102] Hartung TJ, Br€ahler E, Faller H, H€arter M, Hinz A, Johansen C, et al. The risk of
being depressed is signiﬁcantly higher in cancer patients than in the general
population: prevalence and severity of depressive symptoms across major
cancer types [cited 2017 Oct 19] Eur J Cancer 2017 Feb;72:46e53. Available
from:, http://linkinghub.elsevier.com/retrieve/pii/S0959804916325953.
[103] Massie MJ. Prevalence of depression in patients with cancer [cited 2017 Oct
19] J Natl Cancer Inst Monogr 2004 Jul 1;2004(32):57e71. Available from:,
https://academic.oup.com/jncimono/article-lookup/doi/10.1093/
jncimonographs/lgh014.
[104] Akizuki N, Shimizu K, Asai M, Nakano T, Okusaka T, Shimada K, et al. Prev-
alence and predictive factors of depression and anxiety in patients with
pancreatic cancer: a longitudinal study [cited 2017 Oct 19] Jpn J Clin Oncol
2016 Jan;46(1):71e7. Available from:, https://academic.oup.com/jjco/
article-lookup/doi/10.1093/jjco/hyv169.
[105] Kelsen DP, Portenoy RK, Thaler HT, Niedzwiecki D, Passik SD, Tao Y, et al.
Pain and depression in patients with newly diagnosed pancreas cancer [cited
2017 Oct 19] J Clin Oncol 1995 Mar;13(3):748e55. Available from:, http://
ascopubs.org/doi/10.1200/JCO.1995.13.3.748.
[106] Mehnert A, Br€ahler E, Faller H, H€arter M, Keller M, Schulz H, et al. Four-week
prevalence of mental disorders in patients with cancer across major tumor
entities [cited 2017 Oct 19] J Clin Oncol 2014 Nov 1;32(31):3540e6. Avail-
able from:, http://ascopubs.org/doi/10.1200/JCO.2014.56.0086.
[107] Wedding U, Koch A, R€ohrig B, Pientka L, Sauer H, H€offken K, et al. Depression
and functional impairment independently contribute to decreased quality of
life in cancer patients prior to chemotherapy [cited 2017 Oct 19] Acta Oncol
2008 Jan 8;47(1):56e62. Available from:, http://www.tandfonline.com/doi/
full/10.1080/02841860701460541.
[108] Boyd AD, Brown D, Henrickson C, Hampton J, Zhu B, Almani F, et al.
Screening for depression, sleep-related disturbances, and anxiety in patients
with adenocarcinoma of the pancreas: a preliminary study [cited 2017 Oct
19];2012 ScientiﬁcWorldJournal 2012:650707. Available from:, http://www.
hindawi.com/journals/tswj/2012/650707/.
[109] Boyd CA, Benarroch-Gampel J, Shefﬁeld KM, Han Y, Kuo Y-F, Riall TS. The
effect of depression on stage at diagnosis, treatment, and survival in
pancreatic adenocarcinoma [cited 2017 Oct 19] Surgery 2012 Sep;152(3):
403e13. Available from:, http://linkinghub.elsevier.com/retrieve/pii/
S0039606012003030.
[110] Janda M, Neale RE, Klein K, O'Connell DL, Gooden H, Goldstein D, et al.
Anxiety, depression and quality of life in people with pancreatic cancer and
their carers [cited 2017 Oct 19] Pancreatology 2017 Mar;17(2):321e7.
Available from:, http://linkinghub.elsevier.com/retrieve/pii/
S1424390317300200.
[111] Sun V, Ruel N, Chung V, Singh G, Leong L, Fakih M, et al. Pilot study of an
interdisciplinary supportive care planning intervention in pancreatic cancer
[cited 2017 Oct 23] Support Care Cancer 2016 Aug 17;24(8):3417e24.
Available from:, http://link.springer.com/10.1007/s00520-016-3155-9.
[112] Passik SD. Supportive care of the patient with pancreatic cancer: role of the
psycho-oncologist [cited 2017 Oct 19] Oncology (Williston Park) 1996
Sep;10(9 Suppl):33e4. Available from:, http://www.ncbi.nlm.nih.gov/
pubmed/8884806.
[113] Carlson LE, Zelinski E, Toivonen K, Flynn M, Qureshi M, Piedalue K-A, et al.
Mind-Body therapies in cancer: what is the latest evidence? [cited 2017 Oct
19] Curr Oncol Rep 2017 Aug 18;19(10):67. Available from:, http://link.
springer.com/10.1007/s11912-017-0626-1.
[114] de Vries M, Stiefel F. Psychotherapy in the oncology setting [cited 2017 Oct
19] Recent Results Cancer Res 2018;210:145e61. Available from:, http://link.
springer.com/10.1007/978-3-319-64310-6_9.
[115] Wortzel J, Spiegel D. Hypnosis in cancer care [cited 2017 Oct 19] Am J Clin
Hypn 2017 Jul 2;60(1):4e17. Available from:, https://www.tandfonline.com/
doi/full/10.1080/00029157.2017.1290577.
[116] Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the
physiological markers of stress: systematic review and meta-analysis [cited
2017 Oct 19] J Psychiatr Res 2017 Aug 23;95:156e78. Available from:, http://
linkinghub.elsevier.com/retrieve/pii/S0022395617301462.
[117] Fashler SR, Weinrib AZ, Azam MA, Katz J. The use of acceptance and
commitment therapy in oncology settings: a narrative review [cited 2017
A.M. Drewes et al. / Pancreatology 18 (2018) 446e457 457Oct 19] Psychol Rep 2017 Jan 1. 33294117726061. Available from:, http://
journals.sagepub.com/doi/10.1177/0033294117726061.
[118] Qaseem A, Barry MJ, Kansagara D. Clinical guidelines committee of the
American college of physicians. Nonpharmacologic versus pharmacologic
treatment of adult patients with major depressive disorder: a clinical prac-
tice guideline from the American college of physicians [cited 2017 Oct 23]
Ann Intern Med 2016 Mar 1;164(5):350e9. Available from:, http://annals.
org/article.aspx?doi¼10.7326/M15-2570.
[119] Chochinov HM. Dying, dignity, and new horizons in palliative end-of-life
care. CA Cancer J Clin [Internet]. [cited 2017 Oct 16];56(2):84e103-5.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16514136.
[120] Donato SCT, Matuoka JY, Yamashita CC, Salvetti M de G. Effects of dignity
therapy on terminally ill patients: a systematic review [cited 2017 Oct 16]
Rev da Esc Enferm da USP 2016 Dec;50(6):1014e24. Available from:, http://
www.scielo.br/scielo.php?script¼sci_arttext&pid¼S0080-
62342016000601014&lng¼en&tlng¼en.
[121] Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y. Major
depression, adjustment disorders, and post-traumatic stress disorder in
terminally ill cancer patients: associated and predictive factors [cited 2017
Oct 19] J Clin Oncol 2004 May 15;22(10):1957e65. Available from:, http://
ascopubs.org/doi/10.1200/JCO.2004.08.149.
[122] Montgomery GH, Sucala M, Baum T, Schnur JB. Hypnosis for symptom
control in cancer patients at the end-of-life: a systematic review [cited 2017
Oct 19] Int J Clin Exp Hypn 2017 Jul 3;65(3):296e307. Available from:,https://www.tandfonline.com/doi/full/10.1080/00207144.2017.1314728.
[123] World Health Organization. National cancer control programmes. Policies
and managerial guidelines [Internet]. 2002. Available from: http://www.
who.int/cancer/media/en/408.pdf.
[124] Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, et al. Effects of
early integrated palliative care in patients with lung and GI cancer: a ran-
domized clinical trial [cited 2017 Oct 16] J Clin Oncol 2017 Mar 10;35(8):
834e41. Available from:, http://ascopubs.org/doi/10.1200/JCO.2016.70.5046.
[125] Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Inte-
gration of palliative care into standard oncology care: American Society of
clinical oncology clinical practice guideline update [cited 2017 Oct 16] J Clin
Oncol 2017 Jan;35(1):96e112. Available from:, http://www.ncbi.nlm.nih.
gov/pubmed/28034065.
[126] Jang RW, Krzyzanowska MK, Zimmermann C, Taback N, Alibhai SMH. Palli-
ative care and the aggressiveness of end-of-life care in patients with
advanced pancreatic cancer [cited 2017 Oct 16] J Natl Cancer Inst 2015
Mar;(3):107. Available from:, https://academic.oup.com/jnci/article-lookup/
doi/10.1093/jnci/dju424.
[127] Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codeca C, et al.
Systematic versus on-demand early palliative care: a randomised clinical
trial assessing quality of care and treatment aggressiveness near the end of
life [cited 2017 Oct 23] Eur J Cancer 2016 Dec;69:110e8. Available from:,
http://www.ncbi.nlm.nih.gov/pubmed/27821313.
